Ulf Persson (Former)
1 – 50 of 51
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Dread and Risk Elimination Premium for the Value of a Statistical Life
(
- Contribution to journal › Article
- 2018
-
Mark
Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
(
- Contribution to journal › Article
-
Mark
Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype
(
- Contribution to journal › Article
- 2016
-
Mark
Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe
(
- Contribution to journal › Article
-
Mark
Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
(
- Contribution to journal › Article
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
(
- Contribution to journal › Article
-
Mark
The End of the International Reference Pricing System?
2015) In Applied Health Economics and Health Policy(
- Contribution to journal › Article
-
Mark
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
(
- Contribution to journal › Article
- 2014
-
Mark
Willingness to pay for a new drug delivery in Parkinson patients.
(
- Contribution to journal › Article
-
Mark
Costs and Utilities of Manual Therapy and Orthopedic Standard Care for Low Prioritized Orthopedic Outpatients of Working Age: A Cost Consequence Analysis.
(
- Contribution to journal › Article
-
Mark
Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
(
- Contribution to journal › Article
- 2013
-
Mark
Acute pancreatitis - costs for healthcare and loss of production.
(
- Contribution to journal › Article
- 2012
-
Mark
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
(
- Contribution to journal › Article
-
Mark
A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
(
- Contribution to journal › Article
-
Mark
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
(
- Contribution to journal › Article
-
Mark
Budget impact analysis of surgical treatment for obesity in sweden.
(
- Contribution to journal › Article
-
Mark
Drug and treatment costs in Parkinson's disease patients in Sweden.
(
- Contribution to journal › Article
- 2011
-
Mark
Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis Productivity Gain Based on Direct Measurement of Work Capacity before and after 1 Year of Treatment
(
- Contribution to journal › Article
-
Mark
Practical issues in handling data input and uncertainty in a budget impact analysis
(
- Contribution to journal › Article
-
Mark
Acquisition cost of dispensed drugs in individuals with multiple medications A register-based study in Sweden
(
- Contribution to journal › Article
- 2010
-
Mark
A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations.
(
- Contribution to journal › Article
-
Mark
The Value of Informal Caregiver Time for Psychotic Illness
(
- Contribution to journal › Article
-
Mark
Vilken betysdelse har hälsoekonomi vid prioriteringar? Ett experiment bland beslutsfattare och en analys av faktiska prioriteringar.
2010)(
- Book/Report › Report
- 2009
-
Mark
Costs associated with sharps injuries in the Swedish health care setting and potential cost savings from needle-stick prevention devices with needle and syringe.
(
- Contribution to journal › Article
-
Mark
Viktigt hålla fast vid principen om värdebaserad prissättning av läkemedel.
(
- Contribution to journal › Article
- 2008
-
Mark
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
(
- Contribution to journal › Article
- 2005
-
Mark
Obesity, survival, and hospital costs-findings from a screening project in sweden.
(
- Contribution to journal › Article
-
Mark
Den samhällsekonomiska nyttan av cykeltrafikinvesteringar - Förbättring av beslutsunderlag
2005) In Naturvårdsverket Rapport(
- Book/Report › Report
- 2004
-
Mark
Valuing Reductions in the Risk of Traffic Accidents Based on Empirical Studies in Sweden
2004)(
- Thesis › Doctoral thesis (compilation)
- 2003
-
Mark
Long-term follow-up and consequences for severe road traffic injuries - treatment costs and health impairment in Sweden in the 1960s and the 1990s
(
- Contribution to journal › Article
-
Mark
Health-health analysis - An alternative method for economic appraisal of health policy and safety regulation Some empirical Swedish estimates
(
- Contribution to journal › Article
-
Mark
Health-Health Analysis - An Alternative Method for Economic Appraisal of Health Policy and Safety Regulation - Some Swedish Estimates
(
- Contribution to journal › Article
- 2002
-
Mark
Kommunalekonomiska konsekvenser till följd av trafikolyckor : en åttaårsuppföljning av långvariga trafikskador
2002) In Bulletin 208 / 3000(
- Book/Report › Report
-
Mark
International comparison of costs of a fatal casualty of road accidents in 1990 and 1999
(
- Contribution to journal › Article
-
Mark
Costs per Fatal Casualty in Traffic Accidents - an International Comparison of Values used in Traffic Planning
(
- Contribution to journal › Article
- 2000
-
Mark
Värdet av att minska risken för vägtrafikskador : beräkning av riskvärden för dödliga, genomsnittligt våra och lindriga skador med Contingent Valuation metoden
2000) In Bulletin 183 / 3000(
- Book/Report › Report
- 1999
-
Mark
Värdering av icke-dödliga skador till följd av trafikolyckor. Arbetsrapport 4. Skadade registrerade på Lunds sjukhus
1999) In 7177 / 7000(
- Book/Report › Report
-
Mark
Skattning av riskvärden och dödsfallsekvivalenter i vägtrafiken med hjälp av conjoint analysis, risk-risk trade off och standard gamble metoderna : en pilotundersökning
1999) In Bulletin 182 / 3000(
- Book/Report › Report
- 1998
-
Mark
Läkemedelskostnaderna
1998)(
- Book/Report › Report
-
Mark
Värdering av icke-dödliga skador till följd av trafikolyckor. Arbetsrapport 3. Skadade registrerade på Karlskronas sjukhus
1998) In 7176 / 7000(
- Book/Report › Report
- 1997
-
Mark
Kostnader för vägtrafikolyckor i Sverige och värdering av riskreduktioner - en översikt
1997) In Bulletin 144 / 3000(
- Book/Report › Report
-
Mark
Värdet av minskad risk för katastrofer
1997) In 3128 / 3000(
- Book/Report › Report
- 1996
-
Mark
Värdering av icke-dödliga skador till följd av trafikolyckor. Arbetsrapport 1. Skadade registrerade på Lidköpings sjukhus
1996) In 7150 / 7000(
- Book/Report › Report
- 1995
-
Mark
Vilka riskvärden (f.d. humanvärden) bör användas i investeringskalkyler i trafiken?
1995) In Bulletin 128 / 3000(
- Book/Report › Report
-
Mark
Värdet av att minska risken för icke-dödliga trafikskador
1995) In 3101 / 3000(
- Book/Report › Report
-
Mark
Revidering av vägverkets olyckskostnader - en uppräkning till 1997 års priser
1995) In 7141 / 7000(
- Book/Report › Report
- 1994
-
Mark
Minirondeller i Växjö - en ekonomisk utvärdering
1994) In Bulletin 121 / 3000(
- Book/Report › Report
- 1991
-
Mark
The value of risk reduction: results of a swedish sample survey.
1991) In 3075 / 3000(
- Book/Report › Report